Vivesto signs agreement with leading US CRO to evaluate
anti-cancer drug formulations using its proprietary drug delivery platforms

Solna, Sweden, 19 April 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, today announces that it is advancing research into its proprietary drug delivery formulations and has signed a research agreement with Visikol Inc., a leading U.S. contract research services provider (CRO). Visikol will conduct research to evaluate the cellular effects of new and existing anti-cancer drug formulations developed using Vivesto’s proprietary XR-17™ and XR-18 technologies.

As a result of this research, Vivesto will be able to assess anti-cancer compounds formulated with its XR-17™ drug delivery platform as well as line extensions formulated with the XR-18 technology that it is currently developing with regard to their therapeutic properties and underlying biologic effects. This research will allow Vivesto to select promising developmental drug candidates and further expand its current and future oncology pipeline focused on hard-to-treat and late-stage cancers.

Visikol specializes in accelerating the drug discovery and development process by providing its clients with advanced tissue imaging and cell culture services. Visikol has been instrumental in the successful development of dozens of drug discovery programs and counts the top twenty pharmaceutical companies as clients.

Reinhard Koenig, MD, CSO of Vivesto, commented We continue to advance our internal research efforts by developing our XR-17™ and XR-18 technologies, including line extensions and formulations with anti-cancer compounds. We are working hard to achieve a deeper understanding of the cellular effects of these formulations and have therefore partnered with Visikol, an experienced U.S. services company, to provide valuable insights. We are looking forward to integrating the output of this research into the development of new compounds.”

For More Information:
Vivesto AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@vivesto.com

Consilium Strategic Communications (For Vivesto)
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: vivesto@consilium-comms.com

About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.

About Visikol
Visikol is a contract research services company that is focused on accelerating the drug discovery and development process through providing its clients with advanced tissue imaging and advanced cell culture services. Today, Visikol counts the top twenty pharmaceutical companies as clients and has been instrumental in dozens of drug discovery programs. The company provides end-to-end services that include 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, 2D cell culture assays, 3D cell culture assays and ex vivo tissue slice assays. Visikol’s expertise lies in both transforming tissues into actionable insights as well as bridging the gap between in vitro assays and in vivo results through the use of best in-class cell culture models. In addition to its services, Visikol sells a suite of tissue clearing reagents and kits as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models.

2022-05-02T09:17:17-05:00

Share This Page, Choose Your Platform!

This website uses cookies to enhance the user experience. Ok